Immunotherapy of Neuroendocrine Neoplasms: Any Role for the Chimeric Antigen Receptor T Cells?

Area of Science:

• Oncology
• Immunotherapy
• Cellular Therapy

Background:

• Neuroendocrine neoplasms (NENs) are diverse tumors with varied prognoses.
• Surgery is curative but often not feasible due to advanced or metastatic disease at diagnosis.
• Alternative local or systemic treatments are crucial for managing NENs.

Purpose of the Study:

• To review current data on chimeric antigen receptor T cell (CAR-T) therapy for NENs.
• To analyze findings from both preclinical and clinical research.
• To assess the potential of CAR-T therapy in NEN treatment.

Main Methods:

• Conducted a narrative review of relevant scientific literature.
• Searched for published articles, conference abstracts, and registered clinical trials.
• Synthesized data from preclinical models (cell lines, animal models) and clinical studies.

Main Results:

• Preclinical studies demonstrate substantial therapeutic efficacy of CAR-T cells against NENs.
• Early research indicates a significant positive impact in laboratory and animal settings.
• Clinical trials are underway to further evaluate CAR-T therapy's effectiveness.

Conclusions:

• CAR-T therapy presents a potential novel treatment strategy for neuroendocrine neoplasms.
• Preclinical evidence supports its efficacy, warranting further clinical investigation.
• Future clinical trials are essential to establish CAR-T's role in managing aggressive NENs.